Brenda Conceição Guimarães Santana

Brenda Conceição Guimarães Santana

Auto-generated profile, based on publicly available information

Brenda Conceição Guimarães Santana

Laboratório de Proteômica, Departamento de Ciências Biológicas, Universidade Estadual de Santa Cruz, Ilhéus, BA, Brazil

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2023 in Heliyon
Verified
Journal Article
Open access
BSBrenda Conceição Guimarães Santana
Brenda Conceição Guimarães Santana
DMDaisymara Priscila de Almeida Marques
Daisymara Priscila de Almeida Marques
AFAndria Freitas
Andria Freitas
MFMonaliza Macêdo Ferreira
Monaliza Macêdo Ferreira
DLDanielle de Sousa Lopes
Danielle de Sousa Lopes
CPCarlos Priminho Pirovani
Carlos Priminho Pirovani
SARS-CoV-2 is a newly emerging virus from the Coronaviridae family that has already infected over 700 million people worldwide and killed over 6 million. This virus uses protease molecules to replicate and infect the host, which makes these molecules targets for therapeutic substances to eliminate the virus and treat infected people. Through the protein-protein molecular docking approach, we detected two cystatins from Theobroma cacao, TcCYS3 and TcCYS4, described as papain-like protease inhibitors. These inhibitors decreased SARS-CoV-2 genomic copies without toxicity to Vero cells. There is a need to perform comprehensive studies in relevant animal models and to investigate the action mechanisms of protease inhibitors from Theobroma cacao that control the replication of SARS-CoV-2 in human cells.